Probiotics as an alternative to eliminate Pseudomonas aeruginosa biofilm

ArticleAçık Erişim

Özet

Pseudomonas aeruginosa is a clinically important opportunistic pathogen characterized by high antibiotic resistance and strong biofilm-forming capacity, posing a major therapeutic challenge, particularly in immunocompromised patients. In this study, we aimed to evaluate the antibiotic resistance profiles and biofilm-forming abilities of clinical isolates, and to investigate the antibiofilm potential of the probiotic strain Lacticaseibacillus rhamnosus. A total of 66 clinical isolates were analyzed, revealing high levels of antibiotic resistance, while 87.9% of isolates demonstrated biofilm-forming capacity. Treatment with L. rhamnosus at 25% and 50% concentrations resulted in significant antimicrobial and antibiofilm effects. MIC and antibiofilm assays indicated that these effects were dose- and cell density-dependent. Scanning electron microscopy analyses confirmed the structural disruption of biofilms following treatment. Furthermore, real-time PCR results demonstrated that the expression levels of key biofilm-associated genes (algD, pelF, pslD, ppgl, and PAPI-1) were reduced by more than 50%. Importantly, this study provides evidence that L. rhamnosus can effectively inhibit both biofilm formation and biofilm-associated gene expression in multidrug-resistant P. aeruginosa isolates, highlighting its potential as a promising alternative or adjunctive biocontrol strategy against biofilm-related infections. These findings contribute to the growing body of research on probiotic-based approaches targeting antimicrobial resistance and biofilm-associated pathogenicity. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10122Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1007/s10482-026-02391-xYayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorCelebi, Selahattin
dc.contributor.authorCelebi, Ozgur
dc.contributor.authorCelebi, Demet
dc.contributor.authorBaser, Sumeyye
dc.contributor.authorDabanlioglu, Bulent
dc.contributor.authorEktas Kalayci, Sila
dc.contributor.authorAslan, Sumeyye
dc.contributor.authorIslamoglu, Fatma
dc.contributor.authorTaghizadehghalehjoughi, Ali
dc.date.accessioned2026-10-18T20:25:22.601382035Z
dc.date.available2026-10-18T20:25:22.601382035Z
dc.date.issued2026
dc.description.abstractPseudomonas aeruginosa is a clinically important opportunistic pathogen characterized by high antibiotic resistance and strong biofilm-forming capacity, posing a major therapeutic challenge, particularly in immunocompromised patients. In this study, we aimed to evaluate the antibiotic resistance profiles and biofilm-forming abilities of clinical isolates, and to investigate the antibiofilm potential of the probiotic strain Lacticaseibacillus rhamnosus. A total of 66 clinical isolates were analyzed, revealing high levels of antibiotic resistance, while 87.9% of isolates demonstrated biofilm-forming capacity. Treatment with L. rhamnosus at 25% and 50% concentrations resulted in significant antimicrobial and antibiofilm effects. MIC and antibiofilm assays indicated that these effects were dose- and cell density-dependent. Scanning electron microscopy analyses confirmed the structural disruption of biofilms following treatment. Furthermore, real-time PCR results demonstrated that the expression levels of key biofilm-associated genes (algD, pelF, pslD, ppgl, and PAPI-1) were reduced by more than 50%. Importantly, this study provides evidence that L. rhamnosus can effectively inhibit both biofilm formation and biofilm-associated gene expression in multidrug-resistant P. aeruginosa isolates, highlighting its potential as a promising alternative or adjunctive biocontrol strategy against biofilm-related infections. These findings contribute to the growing body of research on probiotic-based approaches targeting antimicrobial resistance and biofilm-associated pathogenicity. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2026.
dc.description.sponsorshipThis study was supported by Erzincan Binali Y\u0131ld\u0131r\u0131m University Scientific Research Projects Coordination with project number TCD-2023\u2013916.
dc.identifier.doi10.1007/s10482-026-02391-x
dc.identifier.eissn1572-9699
dc.identifier.issn0003-6072
dc.identifier.issue8
dc.identifier.pmcid10681627
dc.identifier.pmid42496927
dc.identifier.scopus2-s2.0-105045501898
dc.identifier.startpage173
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10122
dc.identifier.volume119
dc.identifier.wosWOS:001829589400001
dc.language.isoen
dc.publisherSpringer Science and Business Media Deutschland GmbH
dc.relation.ispartofAntonie van Leeuwenhoek, International Journal of General and Molecular Microbiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntibiotic resistance
dc.subjectBiofilm
dc.subjectLacticaseibacillus rhamnosus
dc.subjectPseudomonas aeruginosa
dc.subjectAnti-Bacterial Agents
dc.subjectBiofilms
dc.subjectDrug Resistance, Bacterial
dc.subjectHumans
dc.subjectMicrobial Sensitivity Tests
dc.subjectProbiotics
dc.subjectPseudomonas Infections
dc.subjectamikacin
dc.subjectampicillin
dc.subjectavibactam plus ceftazidime
dc.subjectaztreonam
dc.subjectcefepime
dc.subjectceftazidime
dc.subjectceftriaxone
dc.subjectcefuroxime
dc.subjectcefuroxime axetil
dc.subjectciprofloxacin
dc.subjectcotrimoxazole
dc.subjectimipenem
dc.subjectmeropenem
dc.subjectpiperacillin plus tazobactam
dc.subjectprobiotic agent
dc.subjecttigecycline
dc.subjectantiinfective agent
dc.subjectalgD gene
dc.subjectantibiofilm activity
dc.titleProbiotics as an alternative to eliminate Pseudomonas aeruginosa biofilm
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentFaculty of Medicine Department of Medical Microbiology, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey. | Faculty of Pharmacy Department of Pharmaceutical Microbiology, Erzincan Binali Yıldırım University, 24002, Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)